Difference between revisions of "Part:BBa K4165196"
(→‎Dry lab)
 
(4 intermediate revisions by the same user not shown)
Line 6: Line 6:
  
 
===Usage and Biology===
 
===Usage and Biology===
−
Type of Amyloid-beta binding peptide start from amino acid 35 to 42, this peptide characterized by its solubility which is 149 ± 33 μm.  
+
Segments of amyloid beta fibrils are widely used as a recognition sequence for amyloid beta plaques inside the brain, this is due to the homotypic interactions in the C-terminus of fibrils This binding peptide starts from amino acid 35 to 42 of the fibril.
  
 
===<span class='h3bb'>Sequence and Features</span>===
 
===<span class='h3bb'>Sequence and Features</span>===
 
<partinfo>BBa_K4165196 SequenceAndFeatures</partinfo>
 
<partinfo>BBa_K4165196 SequenceAndFeatures</partinfo>
  
−
===Features and codon optimize===
 
−
This sequence is optimized for E. coli bacteria
 
−
 
−
===Source===
 
−
Homo sapiens Amyloid-beta precursor protein - UniProt (P05067)
 
−
 
−
===References===
 
−
1-Zhao, Y., Cai, J., Liu, Z., Li, Y., Zheng, C., Zheng, Y., ... & Liu, Y. (2018). Nanocomposites inhibit the formation, mitigate the neurotoxicity, and facilitate the removal of β-amyloid aggregates in Alzheimer’s disease mice. Nano letters, 19(2), 674-683.
 
  
 
===Dry lab===
 
===Dry lab===
 
<p style=" font-weight: bold; font-size:14px;"> Modeling </p>
 
<p style=" font-weight: bold; font-size:14px;"> Modeling </p>
−
Due to the nonavailability of a model to this peptide we modeled it in our used modeling software's and after the Running of the quality assessment, the models have been scored to get the top model.
+
The peptide was modeled by several software (Alphafold-Apptest-Pepfold) and the best model from Apptest.
 +
 
  
 
<html>
 
<html>
Line 29: Line 22:
  
 
                                   Figure 1.: Amyloid-beta (35-42) top model visualized by Pymol.
 
                                   Figure 1.: Amyloid-beta (35-42) top model visualized by Pymol.
 +
 +
===References===
 +
1-Zhao, Y., Cai, J., Liu, Z., Li, Y., Zheng, C., Zheng, Y., ... & Liu, Y. (2018). Nanocomposites inhibit the formation, mitigate the neurotoxicity, and facilitate the removal of β-amyloid aggregates in Alzheimer’s disease mice. Nano letters, 19(2), 674-683.
 
    
 
    
  

Latest revision as of 20:00, 11 October 2022


Amyloid beta peptide 16 (Aβ 35-42)

This part encodes a part of the Amyloid 𝛽 fragment (35-42) which has the ability to bind to A𝛽 plaques inside the brain.

Usage and Biology

Segments of amyloid beta fibrils are widely used as a recognition sequence for amyloid beta plaques inside the brain, this is due to the homotypic interactions in the C-terminus of fibrils This binding peptide starts from amino acid 35 to 42 of the fibril.

Sequence and Features


Assembly Compatibility:
  • 10
    COMPATIBLE WITH RFC[10]
  • 12
    COMPATIBLE WITH RFC[12]
  • 21
    COMPATIBLE WITH RFC[21]
  • 23
    COMPATIBLE WITH RFC[23]
  • 25
    COMPATIBLE WITH RFC[25]
  • 1000
    COMPATIBLE WITH RFC[1000]


Dry lab

Modeling

The peptide was modeled by several software (Alphafold-Apptest-Pepfold) and the best model from Apptest. 


                                 Figure 1.: Amyloid-beta (35-42) top model visualized by Pymol.

References

1-Zhao, Y., Cai, J., Liu, Z., Li, Y., Zheng, C., Zheng, Y., ... & Liu, Y. (2018). Nanocomposites inhibit the formation, mitigate the neurotoxicity, and facilitate the removal of β-amyloid aggregates in Alzheimer’s disease mice. Nano letters, 19(2), 674-683.